Fortress Biotech, Inc. - FBIO Revenue Dynamics YoY (Last Twelve Months)

Fortress Biotech, Inc. (FBIO) expanded through the commercialization of orphan drugs, as evidenced by the TTM year-over-year product sales dynamics with a metric value of 12.40. The company subsequently implemented a bio-incubator system to diversify risks via subsidiary structures. The holding company now leverages patent protection and the scale of its ecosystem to successfully navigate stringent FDA requirements while monetizing its oncology assets.
Summary analytical data breakdowns for Fortress Biotech Corp (FBIO)

This indicator reflects revenue growth rates in real time. The calculation is based on a comparison of the current rolling twelve-month window against the same period last year. By analyzing the rolling 12-month sales dynamics year-over-year, an investor eliminates the lag between quarterly reports. For Fortress Biotech, Inc. (FBIO), such sensitivity confirms the resilience of cash flows. The stability of this metric is supported by the defensive qualities of the healthcare sector and the absence of geopolitical risks.